NeuroStemcell is a 4-year FP7 Integrated Project which has been awarded a total budget of 11.9 million € funded by thye European Commission over a 4-year period, 2009-2012, and led by Coordinator Prof. Elena Cattaneo (University of Milan, Italy) and Deputy Coordinator Prof. Anders Björklund at Lund University.
The Consortium comprises 13 academic partners and 3 SMEs from 6 European countries and is formed with the goal to create a world-leading consortium that can develop stem cell based therapies for Parkinson´s disease and Huntington´s disease toward clinical application. Over the 4-year grant period the program aimes to develop safe and validated cells and clinical grade reagents to be used in clinical trials and drug discovery.
NeuroStemcell is focused on the identification and systematic comparison of progenitor cell lines with the most favourable characteristics for mesencephalic dopaminergic and striatal GABAergic neuronal differentiation, generated either directly from human embryonic stem (ES) cells, from induced Pluripotent Stem (iPS) cells, or from neural stem cells derived from either ES cells, iPS cells or fetal brain, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animals models. The Consortium also includes an ethics programme and the development of a road map to the clinic.
Additional information is available at www.neurostemcell.org
Frågor om innehållet: Sara Freoul
Uppdaterad: 2009-04-07
